Monica Shaw
Director/Board Member bei AC IMMUNE SA
Vermögen: 27 084 $ am 31.03.2024
Profil
Monica Shaw is currently an Independent Non-Executive Director at AC Immune SA, a Senior Vice President-Major Markets at Bristol Myers Squibb Co., and the EVP-Head Region Europe, Canada & Australia at LEO Pharma.
A.
She is also a Member of The Royal College of Physicians and the VP-Commercial & Head-Asia Pacific Region at ViiV Healthcare Co. In the past, she was the Chief Executive Officer at Oncopeptides AB and the Medical Director & Chief Scientific Officer-UK at Novartis AG.
Dr. Shaw received a doctorate degree from Oxford University Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AC IMMUNE SA
0,01% | 01.03.2024 | 9 150 ( 0,01% ) | 27 084 $ | 31.03.2024 |
Aktive Positionen von Monica Shaw
| Unternehmen | Position | Beginn |
|---|---|---|
| AC IMMUNE SA | Director/Board Member | 29.10.2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 06.09.2023 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
| ViiV Healthcare Co. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Monica Shaw
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOPEPTIDES AB | Chief Executive Officer | 07.08.2023 |
| Novartis AG /U.S. Biologics Manufacturing Operation/ | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Monica Shaw
| Oxford University Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| AC IMMUNE SA | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Private Unternehmen | 3 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
| Novartis AG /U.S. Biologics Manufacturing Operation/ | Health Technology |
| ViiV Healthcare Co. |
